The development of quantitative and multiplex point-of-care diagnostics

The development of diagnostic kits for point-of-care is important; however, only a few demonstrate needed quantitative and multiplexing capabilities. My laboratories have developed Electrolateral Immunosensor (ELLITM) and StackPadTM to address the aforementioned need. ELLITM is a patented diagnostic technology, amalgamating the concepts of lateral flow with the glucometer, and is combined with our proprietary formulation resulting in a Dengue NS1-validated working prototype for quantitative detection in a sandwich-like format on a screen-printed gold electrodes (SPGE) in less than 30 min. The successful sandwich formation is recorded electrochemically, whereby the signal was contributed by the presence of a redox label, radical TEMPO (TEMPO•), on the
formulated nanoparticles. Meanwhile, another technology, StackPadTM is a novel patent-pending approach on stacked membranes technology. The sample is added onto the bottom-most layer and the analyte flows upward where a specific HRP-tagged antibody is sitting. Through the upward immunocomplex migration and reaction with TMB substrate in the last layer, a measurable optical signal is produced. Overall, the development of ELLITM prototype is a promising start as a rapid, affordable, and sensitive quantitative point-of-care diagnostics technology with no enzyme, whilst StackPadTM serves as a multiplexing platform for its scalable design in a considerably low production cost